 
        
        
        
                货号:A301653
                
                同义名:
                    
                        
                            
                                AZD9668; Avelestat
                            
                        
                    
                
                
                
                    
                     
                    
                     
                
            
Alvelestat是一种中性粒细胞弹性蛋白酶(NE)的选择性抑制剂,pIC50 值为 7.9 nM,具有在炎症疾病和肺部疾病研究中的应用潜力。
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 描述 | Mutations in ELANE, the gene for neutrophil elastase (NE), a protease expressed early in neutrophil development, are the most frequent cause of cyclic (CyN) and severe congenital neutropenia (SCN)[3]. Alvelestat is an orally bioavailable, affinity and selective inhibitor of neutrophil elastase (NE) with a pIC50 value of 7.9 nM, a Ki value of 9.4 nM and a Kd value of 9.5 nM[4]. Alvelestat (20 μg/mL; 16 hours; HBE and A549 cells) treatment decreases cells death and decreases the levels of IL-1β, IL-6, and TNF-αin vitro[5]. Alvelestat (1 - 10 mg/kg; oral administration; twice daily; for 4 days; female BALB/cJBomTac mice) treatment reduces the inflammatory response to cigarette smoke as indicated by a reduction in BAL neutrophils and interleukin-1βin vivo[4]. | 
| Concentration | Treated Time | Description | References | |
| Porcine aortic valve interstitial cells (pVICs) | 40 nmol/L | 24 hours | To investigate the effects of Alvelestat on inflammation, apoptosis, and calcification in pVICs. Results showed that Alvelestat inhibited osteogenic differentiation, inflammation, and apoptosis in pVICs. | J Transl Med. 2022 Apr 9;20(1):167. | 
| Human neutrophils | 10 µM | 1-hour pretreatment followed by 4-hour stimulation | To evaluate the effect of Alvelestat on MSU and PMA-induced neutrophil extracellular trap (NET) formation. Results showed that Alvelestat effectively inhibited NET formation. | Int J Mol Sci. 2024 Dec 27;26(1):143. | 
| Human neutrophils | 10 µM | 1-hour pretreatment followed by 4-hour stimulation | To evaluate the effect of Alvelestat on MSU and PMA-induced neutrophil extracellular trap (NET) formation. Results showed that Alvelestat effectively inhibited NET formation. | Int J Mol Sci. 2024 Dec 27;26(1):143. | 
| Porcine islets | 0–25 μM | 24 hours | To evaluate the inhibitory effect of alvelestat against the cytotoxicity of neutrophil elastase (NE). Results showed that 5 and 25 μM alvelestat recovered the NE-induced decrease in islet viability. | J Clin Med. 2022 Jul 23;11(15):4290. | 
| Administration | Dosage | Frequency | Description | References | ||
| Apoe−/− mice | Western diet-induced aortic valve calcification model | Oral | 3 mg/kg | Once a week for 16 weeks | To investigate the effects of Alvelestat on aortic valve calcification. Results showed that Alvelestat alleviated valve thickening, reduced the expression of NE and α-SMA, and improved heart function. | J Transl Med. 2022 Apr 9;20(1):167. | 
| Mice | Hydrochloric acid aspiration-induced acute lung injury model | Subcutaneous injection | 5 mg/kg | Immediately after acid aspiration, observed for 12 hours | To evaluate the protective effect of Alvelestat on hydrochloric acid aspiration-induced acute lung injury. Results showed that Alvelestat significantly reduced NET formation in lung tissues, decreased inflammatory cytokine levels, and improved lung histopathology. | Oncotarget. 2017 Nov 28;9(2):1772-1784 | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 1.83mL 0.37mL 0.18mL | 9.17mL 1.83mL 0.92mL | 18.33mL 3.67mL 1.83mL | |
| CAS号 | 848141-11-7 | 
| 分子式 | C25H22F3N5O4S | 
| 分子量 | 545.53 | 
| SMILES Code | O=C(C1=CC(C2=CC=NN2C)=C(C)N(C3=CC=CC(C(F)(F)F)=C3)C1=O)NCC4=NC=C(S(=O)(C)=O)C=C4 | 
| MDL No. | MFCD26960961 | 
| 别名 | AZD9668; Avelestat | 
| 运输 | 蓝冰 | 
| InChI Key | QNQZWEGMKJBHEM-UHFFFAOYSA-N | 
| Pubchem ID | 46861623 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C | 
| 溶解方案 | DMSO: 35 mg/mL(64.16 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1